Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Tumour marker measurements in the diagnosis and monitoring of breast cancer
Autore:
Cheung, KL; Graves, CRL; Robertson, JFR;
Indirizzi:
City Hosp, Professorial Unit Surg, Nottingham NG5 1PB, England City Hosp Nottingham England NG5 1PB t Surg, Nottingham NG5 1PB, England
Titolo Testata:
CANCER TREATMENT REVIEWS
fascicolo: 2, volume: 26, anno: 2000,
pagine: 91 - 102
SICI:
0305-7372(200004)26:2<91:TMMITD>2.0.ZU;2-J
Fonte:
ISI
Lingua:
ENG
Soggetto:
CARCINOMA-ASSOCIATED ANTIGEN; METASTATIC BONE-DISEASE; CARCINOEMBRYONIC ANTIGEN; FOLLOW-UP; CA 15-3; THERAPEUTIC RESPONSE; CLINICAL COURSE; SERUM MARKERS; CEA; CA-15-3;
Keywords:
blood tumour markers; measurements; assays; breast cancer; diagnosis, monitoring; therapeutic response; biochemical assessment;
Tipo documento:
Review
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
97
Recensione:
Indirizzi per estratti:
Indirizzo: Robertson, JFR City Hosp, Professorial Unit Surg, Hucknall Rd, Nottingham NG5 1PB, England City Hosp Hucknall Rd Nottingham England NG5 1PB , England
Citazione:
K.L. Cheung et al., "Tumour marker measurements in the diagnosis and monitoring of breast cancer", CANC TR REV, 26(2), 2000, pp. 91-102

Abstract

Elevation of established blood tumour markers correlates with the stage ofbreast cancer. The major role of current blood markers is therefore in thediagnosis and monitoring of metastatic disease. A combination of markers is better than a single marker with the most widely adopted combination being CEA and one MUCI mucin, commonly detected as either CA15.3 or CA27.29. Tumour marker measurement is now used as a complementary test in the diagnosis of symptomatic metastases. in the monitoring of therapeutic response to both endocrine and cytotoxic therapies in advanced disease, biochemical assessment using blood markers not only correlates with conventional UICC criteria but has a lot of advantages which make it a potentially superior way ofassessment. In this regard, CA15.3, CEA and ESR are the best validated combination. Studies are ongoing to evaluate the use of sequential blood tumour marker measurements in the follow-up of patients after treatment for their primarybreast cancer in terms of both early detection and early therapeutic intervention. Further randomized studies are also required to ascertain that marker-directed therapy is superior to the current practice for metastatic disease. in line with clinical studies, intensive laboratory work is being carried out to optimize the use of blood markers in advanced disease as well as to exploit their use in screening and diagnosis of early primary breast cancer. (C) 2000 Harcourt Publishers Ltd.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 26/09/20 alle ore 14:14:33